

Clinical evidence of Talee cranial orthosis has been evaluated for its effectiveness in treating infants with plagiocephaly, brachycephaly or combination of both through a comprehensive retrospective analysis.

The dataset includes **515** patients with complete treatment progress data, treated at partner clinical locations across **19** countries between June 2023 and February 2025.

The average age at the start of treatment was **6.1** months, and the average treatment duration was **3.8** months. The effectiveness was measured comparing the head deformation at the beginning and at the end of 515 treatments.


This sample provides a representative view of real-world clinical outcomes from a diverse patient population.

515	71.5%	28.5%
Patients	Male	Female
19	6.1	3.8
Countries	Average Start Age (Mo)	Average Treatment Duration (Mo)

Plagiocephaly (n = 274)

In severe plagiocephaly CVAI was significantly reduced by **7** points (into a mild category).


In moderate plagiocephaly CVAI was reduced by 4.6 points (normal head shape). And in mild plagiocephaly CVAI was reduced by 3.1 points.



Asymmetrical Brachycephaly (n = 128)


In severe asymmetrical brachycephaly CVAI was significantly reduced by **7.5** points (mild category). In moderate asymmetrical brachycephaly CVAI was reduced by 4.6 points (normal head shape) and in mild starting severity by 3.3 points.

The CI was reduced on average by **7.6** points.



Brachycephaly (n = 113)

In severe brachycephaly CI was significantly reduced by **9.4** points (into mild category). In moderate brachycephaly CI was reduced by 8.6 points (normal head shape).



Conclusion

Talee CRO treatment has shown a consistent and clinically significant improvement in cranial shape. **Talee offers a safe and effective option for correcting all types of positional cranial deformities.**